The company wouldn't know which Provenge preparation was for a placebo arm participant or a Provenge arm participant. They would therefore measure CD54 in all prepared doses and ask for a new leukapheris from any failed batches.
I do not know how the double blind is designed in this patient specific study but it can't be that difficult to place an independent third party between the company and the clinic.
News 
Market Data 
Discover 
